SMITHKLINE SALT-SPARING DIURETIC, SK&F 101926, IS IN CLINICALS
Executive Summary
SMITHKLINE SALT-SPARING DIURETIC, SK&F 101926, IS IN CLINICALS, the company noted in its recently issued annual report for 1985. An IND for U.S. trials was filed in December 1985. SmithKline said that the drug's initial indication will be for severe water retention conditions. The compound acts on vasopressin, a water-regulating hormone that can control the kidney's water output without depleting salt. The vasopressin antagonist "should also have utility in congestive heart failure," the SmithKline report maintains. SmithKline anticipates the first commercial distribution of the recombinant DNA vaccine for hepatitis B, Energix B, during 1986. The company said that "several trials involving more than 3,000 healthy adults and children show virtually total protection against hepatitis B with a three-dose regimen of Energix B." A second recombinant vaccine under study is a circumsporozite antigen vaccine directed at the most severe form of malaria infection, Plasmodium falciparum. The vaccine is being developed jointly with the U.S. Army's Walter Reed Institute for Research. "We have produced the first vaccine for malaria in quantities large enough for clinical trials," the annual report declares. The trials are expected to begin in 1986.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth